The role of entacapone in the management of Parkinson's disease

Hospital Medicine

Volumn 61, Issue 4, 2000, Pages 267-271

  Brooks, David J ^a   Forsvth, Duncan ^a   Plavfer, Jeremv R ^a   Williams, Adrian C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; ENTACAPONE; ENZYME INHIBITOR; LEVODOPA; PLACEBO;

BLOOD; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; PLACEBOS;

EID: 0034168697     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2000.61.4.1315     Document Type: Article

References (15)

1. Adis International Ltd (1999) Comtess'K (Entacapone). A COMT Inhibitor for Treatment of Parkinson 's Disease. Product Monograph. Adis International Ltd, Chester
2. Block G, Liss C, Reines S, Irr J, Nibbelink D (1997) Comparison of immediate-release and controlled release
3. carbidopa/Ievodopa in Parkinson s disease. A multicenter 5-year study. The CR First Study Group. Ear Neural 37: 23-7
4. Dupont E, Andersen A. Boas J et al ( 1996) Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acfa Neuml Scand 93: 14-20
5. Fabbrini G, Mouradian MM, Juncos JL. Schlegel J, Mohr E, Chase TN (1988) Motor fluctuations in Parkinsons disease: central pathophysiological mechanisms, Part 1. Ann Ate
6. Fahn S. Elton R, Members of the UPDRS Development Committee (1987) In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson 's Disease. Vol 2. Macmillan Health Care Information, Florham Park, NJ. USA: 153-63, 293-304
7. Illi A, Sundberg S. Ojala-Karlsson P Scheinin M, Gordin A (I996a) Simultaneous inhibition of catecholamine-Omethylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 51:273-6
8. Illi A, Sundberg S. Ojala-Karlsson P, Scheinin M, Gordin A (1996b) Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 59: 450-7
9. Koller WC, Hubble JP (1990) Levodopa therapy in Parkinson's disease. Neumlogv 40 ( 10 SuppI 3): 40-7
10. Lees AJ (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Br Med .7311:1602-7
11. Nutt JG, Woodward WR, Beckner RM et al ( 1994) Effect of peripheral catechol-O-methyl transferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913-19
12. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neuml 42: 747-55
13. Piccini P. Brooks DJ, Korpela K et al (2000) The COMT inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. .7 Neuml Neurosiirg Psvchialiy (in press)
14. Rinne UK, Larscn JP,'Siden A, Worm-Peterson J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51: 1309-14
15. Ruottinen HM, Rinne UK (1996) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J !\eiti'ol Neui'ostti'g Psvchiülrv 60: 3640